{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:00:57Z","timestamp":1789750857713,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302270"],"award-info":[{"award-number":["82302270"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22171050"],"award-info":[{"award-number":["22171050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022ZD0213800"],"award-info":[{"award-number":["2022ZD0213800"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117981","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T07:33:14Z","timestamp":1752651194000},"page":"117981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of radiolabeling 2-oxo-2-(4-phenylpiperazin-1-yl)acetamide derivatives as potential molecular probes for excitatory amino acid transporter 2"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5885-0280","authenticated-orcid":false,"given":"Pengfei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-7710","authenticated-orcid":false,"given":"Junbin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2813-425X","authenticated-orcid":false,"given":"Yingfang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117981_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.coph.2005.11.004","article-title":"Glutamate- and GABA-based drugs: the next wave of CNS therapeutics?","volume":"6","author":"Foster","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117981_bib2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1152\/physrev.00007.2013","article-title":"Mechanisms of glutamate transport","volume":"93","author":"Vandenberg","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.117981_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101994","article-title":"Neurotransmitter systems in the etiology of major neurological disorders: emerging insights and therapeutic implications","volume":"89","author":"Nimgampalle","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117981_bib4","article-title":"Miniaturized electrochemical sensing platforms for quantitative monitoring of glutamate dynamics in the central nervous system","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem Int Edit"},{"key":"10.1016\/j.ejmech.2025.117981_bib5","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.2174\/0929867321666140916120118","article-title":"The glutamate hypothesis in ALS: pathophysiology and drug development","volume":"21","author":"Blasco","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117981_bib6","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","volume":"11","author":"Foran","year":"2009","journal-title":"Antioxid Redox Sign"},{"key":"10.1016\/j.ejmech.2025.117981_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.expneurol.2007.10.008","article-title":"Amyloid beta peptides and glutamatergic synaptic dysregulation","volume":"210","author":"Parameshwaran","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2025.117981_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.neuint.2004.03.007","article-title":"Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease","volume":"45","author":"Hynd","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2025.117981_bib9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/383634a0","article-title":"Flux coupling in a neuronal glutamate transporter","volume":"383","author":"Zerangue","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117981_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11011-022-01091-5","article-title":"The role of excitatory amino acid transporter 2 (EAAT2) in epilepsy and other neurological disorders","volume":"38","author":"Alijanpour","year":"2023","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.ejmech.2025.117981_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s11064-025-04400-3","article-title":"Excitatory amino acid transporters as therapeutic targets in the treatment of neurological disorders: their roles and therapeutic prospects","volume":"50","author":"Zhang","year":"2025","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2025.117981_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105648","article-title":"The severity of -associated neurodevelopmental disorders correlates with transporter dysfunction","volume":"114","author":"Kovermann","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2025.117981_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249607","article-title":"The regulation of astrocytic glutamate transporters in health and neurodegenerative diseases","volume":"21","author":"Todd","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117981_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.952096","article-title":"EAAT2 as a therapeutic research target in Alzheimer's disease: a systematic review","volume":"16","author":"Wood","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117981_bib15","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/jcp.22609","article-title":"Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics","volume":"226","author":"Kim","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2025.117981_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015430","article-title":"The key role of astrocytes in amyotrophic lateral sclerosis and their commitment to glutamate excitotoxicity","volume":"24","author":"Provenzano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117981_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"\u03b2-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117981_bib18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1172\/JCI66163","article-title":"Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection","volume":"124","author":"Kong","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117981_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.117981_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1021\/acschemneuro.7b00308","article-title":"Identification of novel allosteric modulators of glutamate transporter EAAT2","volume":"9","author":"Kortagere","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117981_bib21","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1021\/acs.jmedchem.3c01909","article-title":"Synthesis and structure-activity relationships for glutamate transporter allosteric modulators","volume":"67","author":"Fontana","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117981_bib22","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1021\/acs.jmedchem.2c00534","article-title":"Discovery of (R)-N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS-1], a novel orally bioavailable EAAT2 modulator with drug- like properties and potent antiseizure activity","volume":"65","author":"Abram","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117981_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1021\/acsmedchemlett.2c00304","article-title":"Design and characterization of novel small molecule activators of excitatory amino acid transporter 2","volume":"13","author":"Das","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117981_bib24","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1016\/j.bmcl.2005.08.003","article-title":"Synthesis and biological activities of aryl-ether-, biaryl-, and fluorene-aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinity glutamate transporter EAAT-2","volume":"15","author":"Greenfield","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ejmech.2025.117981_bib25","article-title":"First-in-human healthy volunteer dosimetry studies of the excitatory amino acid transporter 2 (EAAT2) PET imaging tracer methyl N4-(7-[18F]fluoro-9H-fluoren-2-yl)asparaginate, [18F]RP-115","volume":"142\u2013143","author":"Chao","year":"2025","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117981_bib26","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1021\/acs.jmedchem.2c01572","article-title":"A medicinal chemistry perspective on excitatory amino acid transporter 2 dysfunction in neurodegenerative diseases","volume":"66","author":"Fontana","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117981_bib27","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.ejmech.2025.117981_bib28","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1021\/jm400312y","article-title":"Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand","volume":"56","author":"Zhang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117981_bib29","doi-asserted-by":"crossref","unstructured":"W.H. Cheng Y Fau - Prusoff, W.H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol., 22 3099-3108. doi: 10.1016\/0006-2952(73)90196-2.","DOI":"10.1016\/0006-2952(73)90196-2"},{"key":"10.1016\/j.ejmech.2025.117981_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2025.117981_bib31","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1523\/JNEUROSCI.17-21-08363.1997","article-title":"Glutamate transporter protein subtypes are expressed differentially during rat CNS development","volume":"17","author":"Furuta","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2025.117981_bib32","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1126\/science.276.5319.1699","article-title":"Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1","volume":"276","author":"Tanaka","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117981_bib33","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1021\/acsmedchemlett.9b00655","article-title":"Impact of allosteric modulation in drug discovery: innovation in emerging chemical modalities","volume":"11","author":"Han","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117981_bib34","article-title":"Structural basis of ligand binding modes of human EAAT2","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117981_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32442-6","article-title":"Structural insights into inhibitory mechanism of human excitatory amino acid transporter EAAT2","volume":"13","author":"Kato","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117981_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1021\/acsptsci.8b00057","article-title":"Analytical pharmacology: how numbers can guide drug discovery","volume":"2","author":"Kenakin","year":"2019","journal-title":"Acs Pharmacol Transl"},{"key":"10.1016\/j.ejmech.2025.117981_bib37","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1046\/j.1471-4159.1995.64052193.x","article-title":"Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex","volume":"64","author":"Scott","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejmech.2025.117981_bib38","first-page":"6","article-title":"EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality","author":"Luurtsema","year":"2021","journal-title":"Ejnmmi Radiopharm Ch"},{"key":"10.1016\/j.ejmech.2025.117981_bib39","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1523\/JNEUROSCI.18-21-08751.1998","article-title":"The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain","volume":"18","author":"Lehre","year":"1998","journal-title":"J. Neurosci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:08:30Z","timestamp":1777529310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"alternative-id":["S0223523425007469"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117981","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of radiolabeling 2-oxo-2-(4-phenylpiperazin-1-yl)acetamide derivatives as potential molecular probes for excitatory amino acid transporter 2","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117981"}}